View Older Stories View More Recent Stories
-
J&J wins plaintiff support for $6.5 billion baby powder settlement - Bloomberg
-
Johnson & Johnson (JNJ) Gets Plaintiff Backing For $6.5 Billion Baby Powder Accord - Bloomberg
-
Johnson & Johnson (JNJ) option implied volatility flat into a talc settlement draws near
-
Upside seen for Johnson & Johnson ahead of talc vote outcome
-
Daiwa Securities Downgrades Johnson & Johnson (JNJ) to Neutral (3)
-
Johnson & Johnson (JNJ) seeks U.S. FDA approval of SPRAVATO as the first and only monotherapy for adults with treatment-resistant depression
-
Johnson & Johnson (JNJ) PT Lowered to $185 at TD Cowen
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) PT Raised to $160 at Stifel
-
Midday movers: Nvidia, TSMC, Five Below, Spirit Airlines and Eli Lilly fall
-
Johnson & Johnson (JNJ) gains as Q2 earnings, revenue beat estimates
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance
-
Stocks expected to have increasing option volume: JNJ ELV USB SYF CFG ALLY BE SAVE JBHT
-
Johnson & Johnson (JNJ) call put ratio 5.5 calls to 1 put with focus on July and August 155 calls into quarter results
-
Johnson & Johnson (JNJ) July 149 straddle into quarter results
-
JNJ Q2 earnings preview: This is what analysts expect
-
Legend Biotech said to have received takeover approach, hired Centerview - source
-
Johnson & Johnson (JNJ) Announces Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
-
Emergent BioSolutions (EBS), Johnson & Johnson (JNJ) Settle Claims Over Vaccine Manufacturing Pact - Bloomberg
-
Johnson & Johnson (JNJ) option IV flat into 2024 elections
-
Here are high-quality stock names that pay dividends
-
Johnson & Johnson (JNJ) Reports CARVYKTI achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
-
Johnson & Johnson (JNJ) reports positive results from the nipocalimab Phase 3 Vivacity-MG3 study
-
CHMP issues positive opinion for J&J's (JNJ) BALVERSA for unresectable or metastatic urothelial carcinoma
-
Johnson & Johnson (JNJ) Completes Acquisition of Proteologix
-
Johnson & Johnson (JNJ) Seeking FDA Approval of TREMFYA for Active Crohn's disease
-
Stifel Comments on Johnson & Johnson (JNJ) Post EU Robotic Tour: 'JNJ’s laparoscopic surgery business continues to be on the losing end of robotic share gain'
-
Johnson & Johnson (JNJ): Subcutaneous amivantamab BLA submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) reports TALVEY demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
-
BofA Securities Reiterates Neutral Rating on Johnson & Johnson (JNJ)
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) stock: 1Q24 earnings preview

